Antifungal antibiotics

  title={Antifungal antibiotics},
  author={Monali Gupte and Prasad M. Kulkarni and Babu Ganguli},
  journal={Applied Microbiology and Biotechnology},
Abstract. The search for new drugs against fungal infections is a major challenge to current research in mycotic diseases. The present article reviews the current types of antifungal infections, the current scenario of antifungal antibiotics, and the need and approaches to search for newer antifungal antibiotics and antifungal drug targets. 

Development of antibiotics and the future of marine microorganisms to stem the tide of antibiotic resistance.

Development of the existing antibiotics involved three strategies, including discovery of new target sites, modification of existing antibiotic structures, and the identification of new resources for novel antibiotics.

Antibiotics business: A glimpse

The emergence and spread of antibiotic resistant pathogens has increased substantially over the past two decades, and the development of new antibiotics has decreased alarmingly, because pharmaceutical companies are pulling out of antibiotic research.

Antifungal peptides: Biosynthesis, production and applications

Antifungal peptides are excellent models for drug discovery exhibiting unique characteristics such as high specifi city, broad spectrum, low level of resistance reaching and unique mode of action.

Antimycolytic agents: fungistatic and fungicide

  • Bereda Gudisa
  • Biology, Medicine
    Annals of Dermatological Research
  • 2022
The most routine adverse effects of fluconazole involve accelerated liver enzymes, gastrointestinal complaints, headache, and skin rash, and if antacids, PPIs, H2 blockers administered together with ketoconazole medicines; they will reduce the blood levels of ketoconzole by increasing gastric pH because ketoconAZole requires an acidic media for dissolution and systematic absorption.

Sub-MICs of Carum copticum and Thymus vulgaris influence virulence factors and biofilm formation in Candida spp

The findings have highlighted the concentration dependent activity of oils of C. copticum and T. vulgaris against virulence factors and biofilms in proteinase and haemolysin producing drug-resistant strains of Candida spp.

Production of a growth dependent metabolite active against dermatophytes by Streptomyces rochei AK 39.

The metabolite from Streptomyces rochei AK 39 was produced during late log phase and was active against only dermatophytes with a greater potency than griseofulvin, however, this needs further investigation using purified powdered form of the active component.

Anti-Candida activity of geraniol involves disruption of cell membrane integrity and function.


The fungal strain Fusarium oxysporum produced potent antibacterial bioactive compounds and may be commercially browbeaten for the development of novel drugs.



New potential targets for antifungal development

This review discusses how such approaches are being developed through the identification of novel biochemical and molecular targets to meet the challenges imposed by the scientific research in medical mycology.

Human mycoses: drugs and targets for emerging pathogens.

Fungal infections in humans range flom superficial and cutaneous (such as dermatophytoses) to deeply invasive and dissemi hated (such as candidiasis and cryptococcosis). Pathogenic fungi occur

The new fungal opportunists are coming.

  • J. PerfectW. Schell
  • Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1996
This discussion addresses several issues of pathogenesis, epidemiology, diagnosis, and treatment with regard to these new opportunists, through a review of both general and specific concepts.

Emerging novel antifungal agents.

Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Using the current understanding of the mechanisms of drug resistance as a template, several strategies to overcome resistance have been identified and the development of new antifungal drugs is likely to have the most significant future impact on the management of drug resistant fungi in fungal infections.

L-671,329, a new antifungal agent. I. Fermentation and isolation.

A new lipopeptide antifungal agent, similar to echinocandin B, has been isolated from Zalerion arboricola and studies indicate that L-671,329 is produced under both solid and liquid fermentation conditions.

Resistance of yeasts to azole-derivative antifungals.

  • F. Odds
  • Biology, Medicine
    The Journal of antimicrobial chemotherapy
  • 1993
It must be a matter for concern that, by analogy with the known emergence of antibiotic-resistance among bacteria, that the widespread use of a drug inactive against a particular species may lead to an increased incidence of such infections.

Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance

This review summarizes the factors that contribute to antifungal drug resistance on three levels: clinical factors that result in the inability to successfully treat refractory disease; cellular factors associated with a resistant fungal strain; and molecular factors that are ultimately responsible for the resistance phenotype in the cell.